A new phase 3b clinical trial published in Nature Medicine suggests that orforglipron, a once-daily oral GLP-1 receptor agonist, may help individuals living with obesity maintain weight loss after discontinuing injectable obesity medications. The study highlights the growing importance of long-term obesity management and offers insight into how oral therapies could improve treatment continuity for patients who find injectable medicines difficult to continue over time.
Obesity is increasingly recognized as a chronic and relapsing disease that often requires sustained treatment to maintain health benefits achieved through weight reduction. While injectable therapies such as tirzepatide and semaglutide have demonstrated substantial effectiveness in reducing body weight, maintaining these benefits after stopping therapy remains a challenge. Many individuals experience weight regain once treatment is discontinued, which may reverse improvements in blood pressure, blood sugar, lipid levels, and overall metabolic health.
The ATTAIN-MAINTAIN trial investigated whether switching patients from injectable obesity drugs to oral orforglipron could sustain prior weight loss. Researchers enrolled 376 adults with obesity or overweight and related complications who had completed 72 weeks of tirzepatide or semaglutide in the SURMOUNT-5 trial. Participants were divided into two cohorts: those previously on tirzepatide and those on semaglutide, and then randomized to receive either orforglipron or placebo for 52 weeks. Results showed that orforglipron preserved a substantial proportion of earlier weight reduction compared with placebo. In the tirzepatide cohort, orforglipron maintained nearly 75% of prior weight loss versus 49% with placebo. In the semaglutide cohort, orforglipron maintained about 79% compared with 38% for placebo. Beyond weight, orforglipron helped stabilize cardiometabolic markers, including glycated hemoglobin, fasting glucose, lipid levels, waist circumference, and blood pressure. These findings highlight the clinical importance of maintaining metabolic benefits, as obesity-related complications often worsen with weight regain. The trial suggests that oral orforglipron may be a viable maintenance therapy for patients transitioning off injectable treatments, offering convenience while sustaining health improvements.
Researchers noted that one of the major strengths of orforglipron is its oral formulation. Unlike injectable GLP-1 receptor agonists, the medication does not require injections, refrigeration, or complex administration schedules. The oral format may therefore improve patient convenience, treatment adherence, and accessibility, particularly in individuals who are reluctant to continue injectable therapy. The transition from injectable medication to oral treatment was generally well tolerated. The most commonly reported adverse effects were gastrointestinal symptoms such as nausea, constipation, vomiting, and diarrhea. Most events were mild to moderate in severity, and treatment discontinuation rates remained relatively low. Serious adverse events were uncommon across both treatment groups.
Investigators also highlighted the broader clinical implications of the study. The results reinforce the understanding that obesity management requires long-term therapy rather than short-term intervention. Discontinuation of anti-obesity medication frequently leads to weight regain, similar to what is observed when medications for chronic diseases such as hypertension or diabetes are stopped. The study therefore supports continued treatment strategies that help patients maintain earlier health gains.
Similarly, the SURMOUNT-4 randomized clinical trial by Aronne et al. demonstrated that continued tirzepatide therapy helped maintain substantial weight reduction in adults with obesity, whereas treatment discontinuation resulted in significant weight regain. Comparable findings were observed in the ATTAIN-MAINTAIN trial, where patients transitioning from injectable therapy to oral orforglipron preserved a major proportion of previously achieved weight loss and cardiometabolic improvements. These studies emphasize that sustained pharmacologic therapy is essential for long-term obesity management and support the role of maintenance treatment strategies in preventing weight regain after initial successful weight reduction.
According to the authors, oral orforglipron may provide an effective maintenance option for individuals unable or unwilling to remain on injectable therapies. The researchers concluded that switching from injectable obesity medications to oral therapy could become a practical approach for sustaining weight reduction while improving long-term treatment persistence and patient satisfaction.
Reference
1. Aronne LJ, Horn DB, le Roux CW, Chao AM, Ho W, Halpern B, et al. Orforglipron for maintenance of body weight reduction: the double-blind, randomized phase 3b ATTAIN-MAINTAIN trial. Nat Med. 2026 May 13
2. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48.